TNF and uveitis: The reason may be thatYisaipu® is an TNF receptor fusion protein, while the therapeutic effect of monoclonal antibody anti-TNF agents on extraarticular manifestations such as psoriasis, uveitis and inflammatory bowel disease is better than that of TNF receptor fusion protein.